Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients – Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR

Non-Sponsored Content

TARGETED THERAPY

Capivasertib added to fulvestrant improves in progression-free survival advanced breast cancer patients

Medical writer: Christy HC CHEUNG, BSc | Last updated: 19th February 2020 | In: Breast Cancer, Endocrine Therapy, Oncology, Targeted Therapies

Article Keywords

AKT, AKT inhibitor, AKT1, AZD5363, breast cancer, capivasertib, Faslodex, fulvestrant, paclitaxel, PIK3CA, PTEN, TNBC

Adding capivasertib to fulvestrant improves the progression-free survival (PFS) in postmenopausal women with oestrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer resistant to aromatase inhibitors, concluded Jones et al. (2020) in Lancet Oncology.¹

“FAKTION met its primary outcome in showing that the combination of fulvestrant and capivasertib is tolerable and produces a significant improvement in progression-free survival for participants with advanced oestrogen receptor-positive HER2-negative breast cancer who have previously progressed on an aromatase inhibitor,” first author Dr Jones, and his colleagues wrote in The Lancet Oncology.¹.

FAKTION Trial

The double-blind phase II FAKTION trial (NCT01992952) randomised 140 patients 1:1 to either capivasertib plus fulvestrant (n=69) or placebo plus fulvestrant (n=71).¹ Eligible patients included postmenopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer that had relapsed or progressed on — or within 12 months of — adjuvant aromatase inhibitor therapy in the metastatic setting. Patients previously treated with fulvestrant or inhibitors of the PI3K/AKT pathway, or those with clinically significant abnormalities of the glucose metabolism were excluded. The primary efficacy endpoint was PFS. Patients were stratified according to the PI3K/PTEN pathway alteration status.

Results

The median PFS was 10.3 months in the capivasertib plus fulvestrant group, and 4.8 months in the placebo group (HR=0.58; 95% CI, 0.39–0.84; two-sided p=0.0044; one-sided log-rank test p=0.0018) in favour of the capivasertib group.

Interestingly, the addition of the AKT-inhibitor capivasertib to fulvestrant did not show a pronounced efficacy in the subgroup of patients with alterations in the Pi3K/PTEN pathway; the median PFS measured 9.5 months in the capivasertib group and 5.2 months in the placebo group. The outcome in the patients without Pi3K/PTEN alterations was similar to the overall result; a median PFS of 10.3 months vs 4.8 months for capivasertib plus fulvestrant vs placebo plus fulvestrant, respectively.

Safety

The most common grade ≥3 adverse events included hypertension (32% vs 24%), diarrhoea (14% vs 4%), rash (20% vs 0), and infection (6% vs 3%) in patients receiving capivasertib and fulvestrant vs those receiving placebo and fulvestrant, respectively. Serious adverse reactions only occurred in the capivasertib group, and included acute kidney injury (n=2), diarrhoea (n=3), rash (n=2), hyperglycaemia (n=1), loss of consciousness (n=1), sepsis (n=1), and vomiting (n=1). There was one death of unknown cause in the capivasertib group.

Reference

Jones RH, et al. Lancet Oncol. 2020 pii: S1470-2045(19)30817-4.

Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

Sotorasib approved as the first targeted therapy for Lung Cancer

Amivantamab in combination with Lazertinib showed efficacy in NSCLC

ASCO GI Webinar: Update on NET and HCC

ASCO 2021 Liver Cancer Update

22nd November 2021